San Francisco startup Composition Therapeutics is additionally focusing on an oral, after-daily GLP-1 drug called GSBR-1290—the drug surpassed Wall Avenue’s expectations in June when a mid-stage research showed average weight loss of all over 6% and it programs to start An additional mid-stage demo towards the end of this yr—that founder and